Artesunate and Amodiaquine Tablets are a fixed‑dose artemisinin‑based combination therapy (ACT) widely recommended for the treatment of acute uncomplicated malaria.
Artesunate: A fast‑acting artemisinin derivative that rapidly reduces parasite load and relieves fever and clinical symptoms.
Amodiaquine: A long‑acting 4‑aminoquinoline that eliminates residual parasites and prevents recurrence.
The two components act synergistically to achieve high cure rates and delay the development of drug resistance.
Indications
For the treatment of acute uncomplicated malaria caused by Plasmodium falciparum (including chloroquine‑resistant strains) and Plasmodium vivax in adults and children.
Key Features
Rapid parasite clearance and quick symptom relief
High efficacy and low recurrence rate
Well‑tolerated safety profile
Convenient oral administration, usually a 3‑day treatment course
Suitable for use in malaria‑endemic regions
Manufactured under strict GMP standards
Complies with WHO, USP, EP and international pharmacopoeial standards
Complete registration dossiers available for global markets
Storage
Store in a cool, dry place, protected from light and moisture.
Keep out of reach of children.
Important Note
Prescription‑only medicine.
Contraindicated in patients with hypersensitivity to artesunate, amodiaquine, or other quinoline derivatives.
Use with caution in patients with hepatic or renal impairment, hematological disorders, or G6PD deficiency.
Not suitable for severe malaria; parenteral antimalarials are required.
Administer under medical supervision.
